See more : Wei Chih Steel Industrial Co., Ltd. (2028.TW) Income Statement Analysis – Financial Results
Complete financial analysis of Enfusion, Inc. (ENFN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Enfusion, Inc., a leading company in the Software – Application industry within the Technology sector.
- Viking Therapeutics, Inc. (VKTX) Income Statement Analysis – Financial Results
- Edison International (EIX) Income Statement Analysis – Financial Results
- ACCENTRO Real Estate AG (A4Y.DE) Income Statement Analysis – Financial Results
- Anika Therapeutics, Inc. (ANIK) Income Statement Analysis – Financial Results
- Xiangtan Electric Manufacturing Co. Ltd. (600416.SS) Income Statement Analysis – Financial Results
Enfusion, Inc. (ENFN)
About Enfusion, Inc.
Enfusion, Inc. provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. It provides portfolio management system, which generates a real-time investment book of record that consists of valuation and risk tools that allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and order and execution management system that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines. The company also offers accounting/general ledger system, a real-time accounting book of record for chief financial officers, chief operating officers, accountants, and operations teams; Enfusion analytics system, which enables CIOs, portfolio managers, traders, and analysts to analyze portfolios through time horizons and automate customized visualized reports for internal and external stakeholders; and technology-powered and managed services. Enfusion Inc. was incorporated in 2021 and is headquartered in Chicago, Illinois.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
---|---|---|---|---|---|
Revenue | 174.54M | 150.35M | 111.70M | 79.57M | 59.03M |
Cost of Revenue | 57.64M | 47.10M | 31.85M | 21.36M | 16.96M |
Gross Profit | 116.89M | 103.25M | 79.86M | 58.21M | 42.07M |
Gross Profit Ratio | 66.97% | 68.67% | 71.49% | 73.16% | 71.27% |
Research & Development | 19.89M | 17.16M | 153.40M | 6.32M | 4.15M |
General & Administrative | 64.64M | 68.76M | 150.61M | 35.89M | 16.63M |
Selling & Marketing | 20.42M | 29.29M | 51.73M | 9.93M | 7.43M |
SG&A | 85.05M | 98.05M | 202.34M | 45.82M | 24.05M |
Other Expenses | 0.00 | -638.00K | -1.19M | 82.00K | -3.00K |
Operating Expenses | 104.95M | 115.21M | 355.74M | 52.13M | 28.20M |
Cost & Expenses | 162.59M | 162.31M | 387.58M | 73.49M | 45.16M |
Interest Income | 0.00 | 413.00K | 4.59M | 1.66M | 724.00K |
Interest Expense | 0.00 | 413.00K | 4.59M | 1.66M | 724.00K |
Depreciation & Amortization | 9.99M | 6.60M | 3.98M | 2.29M | 1.16M |
EBITDA | 21.94M | -5.62M | -271.91M | 8.37M | 15.02M |
EBITDA Ratio | 12.57% | -3.74% | -244.49% | 10.62% | 25.45% |
Operating Income | 11.95M | -11.96M | -275.88M | 6.07M | 13.87M |
Operating Income Ratio | 6.85% | -7.96% | -246.99% | 7.63% | 23.50% |
Total Other Income/Expenses | -464.00K | -225.00K | -5.78M | -1.58M | -727.00K |
Income Before Tax | 11.48M | -12.19M | -281.66M | 4.49M | 13.14M |
Income Before Tax Ratio | 6.58% | -8.11% | -252.16% | 5.65% | 22.26% |
Income Tax Expense | 2.23M | 1.07M | 579.00K | 433.00K | 486.00K |
Net Income | 6.03M | -13.26M | -282.24M | 4.06M | 12.66M |
Net Income Ratio | 3.45% | -8.82% | -252.68% | 5.10% | 21.44% |
EPS | 0.10 | -0.16 | -4.30 | 0.04 | 0.11 |
EPS Diluted | 0.07 | -0.16 | -4.30 | 0.04 | 0.11 |
Weighted Avg Shares Out | 88.20M | 85.39M | 65.58M | 113.05M | 113.05M |
Weighted Avg Shares Out (Dil) | 129.43M | 85.39M | 65.58M | 113.05M | 113.05M |
Shareholders Are Encouraged To Join The Schall Law Firm's Inquiry Into Enfusion, Inc. For Possible Securities Fraud
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Enfusion, Inc. - ENFN
Enfusion Inc Is Being Investigated For Violating Securities Laws And The Schall Law Firm Seeks Investor Participation
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Enfusion, Inc. - ENFN
The Schall Law Firm Is Inquiring Into Enfusion, Inc. For Possible Securities Fraud And Stockholders With Losses Should Take Part
Enfusion Inc May Have Violated Securities Laws And The Schall Law Firm Wants Impacted Investors To Reach Out
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Enfusion, Inc. - ENFN
Shareholders Are Urged To Join The Schall Law Firm's Investigation Into Enfusion, Inc. For Possible Securities Fraud
Enfusion Inc Is Being Looked Into For Violating Securities Laws And The Schall Law Firm Invites Investors To Reach Out
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Enfusion, Inc. - ENFN
Source: https://incomestatements.info
Category: Stock Reports